logo
Share SHARE
FONT-SIZE Plus   Neg

BioSante Pharma Reveals Positive Results Of Its Prostate Cancer Vaccine Study

Specialty pharmaceutical company BioSante Pharmaceuticals Inc (BPAX) Monday announced that the latest issue of The Lancet Oncology published the results from a Phase I dose escalation clinical study of GVAX Prostate cancer vaccine.

The results revealed that the GVAX Prostate cancer vaccine, used in treating metastatic castration-resistant prostate cancer patients in combination with ipilimumab, resulted in 53 percent of patients achieving at least stable disease, with two patients showing clear regression of metastases.

The results further revealed that 23 percent of patients in the higher dose cohorts had confirmed partial PSA response of greater than 50 percent from baseline.

The study further concluded that there were no serious adverse events in the lower dose Ipi cohorts and administration of immunotherapy was well tolerated and safe.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Nike Inc. (NKE), the world's largest athletic shoes and apparel maker, Tuesday said its first-quarter profit rose 6 percent from a year ago, driven largely by higher revenues. Shares of the company slipped over 6 percent in the after-hours trading, hurt by weak futures orders. Beaverton, Oregon-based... Germany, a clean-power trendsetter country, is planning to introduce hydrogen powered trains. The environment friendly "Coradia iLint" long distance passenger hydrails are expected to be operational by the end of 2017. Rogers Communications Inc. and Shaw Communications Inc. are shutting down Shomi, the subscription video-on-demand service run by the two Canadian companies. Shomi said it will shut down operations on November 30, 2016, just two years since its launch. Shomi was viewed as a Canadian competitor to Netflix.
comments powered by Disqus
Follow RTT